



**Detection of cardiovascular disease associated miR-29a
using paper-based microfluidics and surface enhanced
Raman scattering**

Journal:	<i>Analyst</i>
Manuscript ID	AN-ART-09-2019-001748.R1
Article Type:	Paper
Date Submitted by the Author:	17-Nov-2019
Complete List of Authors:	Mabbott, Samuel; Texas A&M University College Station, Biomedical Engineering Fernandes, Syrena; Tufts University, Chemistry Schechinger, Monika; Texas A&M University College Station, Biomedical Engineering Cote, Gerard; Texas A&M University, Biomedical Engineering Faulds, Karen; University of Strathclyde, Department of Pure and Applied Chemistry Mace, Charles; Tufts University, Chemistry Graham, Duncan; University of Strathclyde, Department of Pure and Applied Chemistry

Detection of cardiovascular disease associated miR-29a using paper-based microfluidics and surface enhanced Raman scattering

Samuel Mabbott^{1,3,4}, Syrena C. Fernandes², Monika Schechinger^{3,4}, Gerard L. Cote^{3,4}, Karen Faulds¹, Charles R. Mace² and Duncan Graham^{1*}

1. Department of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, 99 George Street, Glasgow, G1 1RD, UK.
2. Department of Chemistry, Tufts University, 62 Talbot Avenue, Medford, MA 02155, US
3. Department of Biomedical Engineering, Texas A&M University, MS 3120, College Station, Texas, 77842-3120, US
4. Health Technology and Innovation Building, Texas A&M University, MS 3006, College Station, Texas, 77843-3006

*Corresponding author

Abstract

The development of viable point-of-care diagnostic formats is integral to achieving better patient care and improved outcomes. The need for robust and low-cost tests is especially important in under-resourced and rural settings. Perhaps the greatest challenge is ensuring that an untrained individual is capable of operating and interpreting the test, out with a care facility. Here we present a paper-based diagnostic device capable of sensing miR-29a using both colorimetric and surface enhanced Raman scattering (SERS) analysis. Rather, than carry out the two types of analyses in tandem, we envisage that the colorimetric output is easy enough to be interpreted by the untrained-individual administering the test to provide them with qualitative feedback. If deemed positive, the test can be further validated at a centralized care facility using a handheld-Raman spectrometer to provide a semi-quantitative result. Detection of miR-29a, a microRNA associated with myocardial infarction, was achieved at a level of pg/ μ L through the combination of three-dimensional paper-based microfluidics, colorimetric detection, and surface enhanced Raman scattering (SERS) analysis. RGB analysis of the colorimetric output generated from samples containing miR-29a at different concentrations (18-360 pg/ μ L) showed differentiation from the control sample, however significant repeat variability indicated that it could not be used for quantifying miR-29a levels. However, the SERS analysis exhibited greater reproducibility at varying concentrations, achieving an LoD of 47 pg/ μ L. The union of the paper-based device and the two analysis methods resulted in the production of a sensitive, reproducible and facile, point of care test (POCT), which paves the way for future implementation in the diagnosis of a range of diseases.

Introduction

According to the World Health Organization (WHO), cardiovascular diseases (CVDs) account for 31% of all global deaths.¹ Statistics from 2017 suggest that around every 40 seconds someone in the United States has a heart attack (myocardial infarction or MI) caused by reduced blood flow to the heart muscle due to blockages in the surrounding arteries. It is estimated that 790,000 Americans suffer from a heart attack and for around 73% of them it is their first. This

1
2
3 causes permanent damage to the muscle tissue, the extent of which is dependent on the size of
4 the blockage and the time between the occurrence and treatment. Clinicians are able to assess
5 a patient's CVD risk by evaluating a range of non-invasive values (body mass index and systolic
6 blood pressure) as well as assessing personal and family medical histories. To get more detailed
7 information for CVD diagnosis, clinicians will utilize blood panels to assess cholesterol and plasma
8 ceramide levels or will carry out chest X-rays, echocardiograms and electrocardiograms.^{2, 3 4}
9 Conducting in-depth analysis for CVD diagnosis requires sophisticated instrumentation and
10 trained healthcare practitioners. The requirement for advanced infrastructure and support in a
11 centralized facility presents a significant challenge, particularly in underserved areas that are in
12 remote locations and/or are of low economic status. It is now well recognized that there is an
13 immediate need for targeted testing worldwide, particularly in these underserved populations
14 who are at increased risk of CVD due to contributors such as higher rates of hypertension, obesity
15 and diabetes.⁵ It is thought that improved diagnostic testing of CVD—ideally using affordable
16 tests that can be used by anyone and anywhere—is integral to improving patient care and
17 outcomes.⁶

18
19
20
21
22 Point-of-care testing (POCT) is performed to address accessibility challenges outside of
23 the usual clinical laboratory setting. This type of testing can also be applied discreetly at a
24 patient's location for rapid results and informed treatment. Several technologies that enable the
25 detection of CVD biomarkers are being used at the point-of-care. One example is the Roche cobas
26 b 101 system capable of testing for hemoglobin A1c, lipids, and c-reactive protein within 15
27 minutes from small volumes of blood.⁷ Similarly, Abbott's I-STAT handheld blood analyzer system
28 is able to test blood for cardiac troponin I and B-type natriuretic peptide (BNP).⁸ Although both
29 of these systems are considered to enable POCT, their cartridge format and reliance on expensive
30 and dedicated readers severely restricts the broader use of such technologies.

31
32
33 To guide the development of accessible POCT, the WHO established the ASSURED criteria
34 (Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free, and Deliverable
35 to end users).⁹ The acronym was originally formulated to address issues associated with the
36 detection of sexually transmitted diseases, but is now more broadly applied for the design of 'in-
37 field' tests for the diagnosis of a range of disease and infections. Recently, the ASSURED criteria
38 has been updated to REASSURED,¹⁰ which acknowledges the importance of "Real-time
39 connectivity" that can be accomplished in some cases using external devices such as mobile
40 phones and "Ease of specimen collection and environmental friendliness" for instance by
41 eliminating the use of non-recycled plastics that often give out toxic fumes when burned. Lateral
42 flow tests (LFTs) satisfy many of the ASSURED criteria and as a result have formed the basis for
43 numerous single-use POCTs with applications in field-based healthcare settings (e.g., malaria,
44 influenza) and direct consumer markets (e.g., pregnancy, HIV).¹¹⁻¹⁴ Coupled with an abundance
45 of target specific biomolecules, including DNA,¹⁵⁻¹⁸ antibodies^{19, 20} and aptamers,²¹ LFTs offers
46 potential solutions for the clinical diagnosis of CVD at the point-of-care.^{22, 23} LFTs have shown
47 significant promise towards the sensitive and specific detection of cardiac troponin (cTnI) and
48 high sensitivity C-reactive protein, with both markers being clinically validated.²⁴⁻²⁶ The
49 colorimetric output associated with many LFTs also lends itself extremely well to the semi-
50 quantitative evaluation of the biomarker levels. However, LFTs have several disadvantages that
51 create obstacles to their application in CVD. First, signal generation requires the affinity-based
52 capture of reagents (e.g., colloidal particles), which makes it difficult to create tests for metabolic
53
54
55
56
57
58
59
60

1
2
3 biomarkers.²⁷ Second, multiplexing is problematic because reagents are co-formulated for
4 storage in a common pad and all assays must be performed in a common fluidic pathway. As a
5 result, most LFTs are limited to 1–3 test lines per device.
6

7 To address these challenges, paper-based microfluidic devices have been developed as
8 an alternative technology to LFTs.²⁸⁻³⁰ Paper can be easily patterned with hydrophobic barriers
9 to control the distribution of a sample within a device and support the storage of assay reagents
10 in spatially-separated zones. Three-dimensional microfluidic networks can be created by stacking
11 multiple layers of patterned paper or by making a series of folds in a single sheet of paper, much
12 like origami.^{29, 31} Both approaches enable multi-step assays that are not easily accessible in LFTs.
13 Paper-based microfluidic devices facilitate the development of a wide range of diagnostic assays
14 that can utilize a variety of methods to transduce measurable signals such as electrochemical,
15 fluorescent, and/or colorimetrics.³² This inherent adaptability of paper-based microfluidic
16 platforms can also permit the combination of multiple assay strategies simultaneously within a
17 single device or even a single test zone. Further, paper has the potential to be more
18 environmentally friendly over standard plastic materials.
19

20
21 Here we demonstrate such a strategy by developing an assay for the detection of miR-
22 29a, a microRNA (miRNA) biomarker of CVD, in a three-dimensional paper-based microfluidic
23 device that combines both colorimetric and SERS readouts using gold nanoparticle-based
24 reagents. Elevated levels of the short non-coding RNA molecule miR-29a have been shown to be
25 associated with the onset of diverse cardiovascular and cerebrovascular diseases, including
26 vascular inflammation, myocardial infarction, and heart failure. One major advantage of miR-29a
27 as a biomarker for CVD is that, unlike other miRNAs that are confined to cell nuclei, it can be
28 found circulating freely in the bloodstream.³³ As a result, detection of miR-29a may be possible at
29 the point-of-care where fingerstick sampling of blood is routine.
30
31

32 In the combined approach for measuring this biomarker, the generation of a colorimetric
33 result can be interpreted by the person carrying out the testing (i.e., qualitatively), allowing the
34 test to be performed in environments that lack access to instrumentation. The result will then
35 inform the person as to whether further evaluation and treatment is needed. It is envisaged that
36 a result validation procedure could be carried out using a Raman instrument contained within a
37 centralized healthcare unit. When paired with a handheld Raman instrument, we show that SERS
38 analysis can validate the colorimetric results and achieve improved signal reproducibility, which
39 offers the potential for a quantitative paper-based assay. Further, with commercial Raman
40 instruments being made smaller and becoming more affordable, the use of both modalities at
41 the POC is a near-future possibility for an inexpensive and accessible POCT for CVD.
42
43
44
45

46 **Experimental**

47 **Synthesis of Gold Nanoparticles (AuNPs)**

48 AuNPs were synthesized using a citrate reduction method. To 100 mL of deionized water,
49 sodium tetrachloroaurate (III) dihydrate (4 mg, 0.1 mM) was added and heated. Once boiling, 7.5
50 mL of trisodium citrate dihydrate (84 mg, 38 mM) was added and the solution was allowed to
51 boil under vigorous stirring for 15 mins. The appearance of a red sol signified the formation of
52 AuNPs. Extinction spectroscopy revealed a λ_{\max} = 521 nm and absorbance of 0.505. According to
53 published results the nanoparticles were estimated to be ~20 nm in diameter.³⁴ The
54
55
56
57
58
59
60

1
2
3 concentration of the nanoparticles was calculated to be 0.5 nM using an extinction coefficient of
4 9.28×10^8
5

6 7 **Functionalisation of the AuNPs with DNA and MGITC**

8 The AuNPs were functionalized using single-stranded 5'thiol-modified DNA with 3
9 hexaethylene glycol spacers incorporated to separate the DNA from the thiol terminal group. The
10 strand consisted of 10 bases and represents around half of the complementary sequence of miR-
11 29a. To allow for fast attachment of the thiolated-DNA to the NP surface, a pH-assisted
12 methodology was employed. To 1 mL of AuNPs, 30 μ L of monothiolated DNA was added at a
13 concentration of 5000 oligos per NP, immediately after DNA addition 60 μ L of citrate buffer was
14 added (0.3 M, pH 3) and the sol was left to shake for 30 mins. The DNA functionalized
15 nanoparticles were centrifuged for 20 mins at 6000 rpm and the supernatant was removed and
16 replaced with 0.1 M PBS, pH 7.4. The centrifugation steps and supernatant replacement was
17 carried out twice more to ensure the removal of unbound DNA.
18

19 In order to acquire a SERS read out it was crucial that the DNA conjugated AuNPs were
20 modified using a Raman reporter. In this case malachite green isothiocyanate (MGITC) was
21 chosen, as it forms a strong attachment to the nanoparticles surface via its isothiocyanate group.
22 The modified nanoparticles were mixed with MGITC dye at \sim 5000 molecules per NP for 2 h. The
23 number of oligos and dye molecules per nanoparticle were calculated based on the AuNP
24 concentration of 0.5 nM.
25

26 Following the successful modification of the NPs with single stranded DNA and dye, they
27 were then centrifuged for 20 min at 6000 rpm and resuspended in a buffer containing sodium
28 phosphate (20 mM), TWEEN 20 (0.25% v/v) and sucrose (10% w/v) at an optical density (O.D.) of
29 7. Additives in the suspension buffer stabilizes the nanoparticles while ensuring they will not stick
30 to the papers fibers when flowing though the microfluidic channels.
31
32
33
34

35 **Preparation of wax printed layers.**

36 The three-dimensional paper-based microfluidic devices are assembled from a
37 combination of Whatman 4 chromatography paper (W4C), immunodyne ABC nylon membrane
38 (0.45 μ M pore size) and Fisherbrand chromatography paper (FCP, 0.35 mm thickness). The device
39 is composed of 6 wax-patterned layers, which define hydrophilic and hydrophobic zones on the
40 paper and control solution follow throughout the device. Wax is deposited onto the paper using
41 a Xerox ColorQube 8580 printer. The wax-coated paper is then heated in an oven at 150 $^{\circ}$ C for
42 30 s, until the wax has penetrated completely through to the other side.
43
44

45 Figure 3 shows the layer architecture and the black/yellow zones indicate the areas where
46 wax has been deposited. From top-to-bottom the 3-D device is composed of a sample addition
47 layer (W4C), this is where the solution sample is introduced and shields the device from
48 environmental contamination. The conjugate layer (W4C) stores the signal transducing reagent
49 (DNA-modified AuNPs). The incubation layer (W4C) promotes the binding between the
50 biofunctionalized NPs and the miRNA as the sample travels laterally. The capture layer (nylon
51 membrane) features immobilized ssDNA oligo strands. It is here that nanoparticles will be
52 retained if the miR-29a sequence is present in a sample. After the assay is complete, this layer is
53 revealed to enable visualization and spectral interrogation of the test result. The wash layer
54
55
56
57
58
59
60

1
2
3 (W4C) wicks free sample and reagents away from the capture layer into the blot layer (FCP). Each
4 layer is backed using double-sided adhesive tape to attach the layers together.

5
6 The functionalized AuNPs (5 μL , OD 7) were deposited onto the conjugate storage layer,
7 suspension buffer (15 mL) was spotted onto the incubation layer and streptavidin (1 mg/mL, 1
8 μL) followed by biotin modified single stranded DNA (12 bases, 5 μL , 12.5 μM) was added
9 sequentially to the capture layer. This layer was washed with 0.3 M PBS to remove any unbound
10 Biotin-ssDNA. The streptavidin-biotin complex is not washed through the layer because its large
11 size is unable to navigate through the pores of the nylon. Which means that it is available to
12 hybridize to the complementary miR-29a sequence when the assay is run

13
14 All layers were left to dry (~30 mins) before running the assay. The adhesive backing on
15 each layer was revealed and the device constructed according to Figure 3. Other layers not
16 mentioned above include the self-explanatory sample addition layer and also the wash and wick-
17 pad, which pull the assay solution through the assembled device by capillary action.

20 **Running of the device**

21
22 Once assembled, the device is rolled through a cold laminator to ensure that the layers
23 are in satisfactory conformal contact to enable the flow of solution throughout. An assay is
24 carried out on the device by first spotting a sample onto the sample addition layer. In the
25 experiments carried out here, this usually involves the deposition of either complementary (miR-
26 29a) or non-complementary (miR-21, negative control) miRNA, followed by PBS (40 μL , 0.3 M).
27 The PBS solution is referred to as the running buffer. It takes around 20 mins to run a single
28 device, after which time the capture layer is peeled back to reveal the result. The capture layer
29 is left to dry fully for a further 30 mins before SERS analysis is carried out.

32 **SERS Analysis**

33
34 SERS analysis is carried out using a CBEX handheld Raman spectrometer (Snowy Range
35 Instruments, Laramie, USA). The handheld device operates at 638 nm (40 mW) and is equipped
36 with a point and shoot adjustable tip. The distance from the device aperture to tip end is set at
37 ~26 mm, this was found to be the optimal distance for SERS interrogation of the detection layer
38 of the paper based devices. Spectra were acquired for 0.01s, in orbital raster scan mode over a
39 range of 400-1700 cm^{-1} . A 3D printed (PLA) adaptor was created to ensure consistent collections
40 were made. **Figure 2** shows the handheld Raman instrument together with the adaptor. Raw
41 Raman data were extracted in spc format and processed in Matlab (Mathworks, MA, USA).
42 Initially, the spectra were cropped to display the 1100-1700 cm^{-1} region which contained
43 vibrational bands of interest for MGITC. The spectra were then baseline corrected using an
44 asymmetric least squares algorithm.³⁵ To generate the concentration curve (Figure 4B) the
45 intensity of the benzene in-plane vibration at 1174 cm^{-1} was used. The intensities of these peaks
46 were isolated from the data sets and averaged for each repeat concentration and their standard
47 deviations were calculated to show the variation in signal. The curve fitted to the data is
48 generated using a 2nd order polynomial in Matlab.

53 **Results and Discussion**

54 Sensing of the miR-29a strand is achieved using a split-probe hybridization assay. The schematic
55 in **Figure 1** shows the assay design. Initially, a 22 base single strand DNA complement is
56
57
58
59
60

1
2
3 established for the miR-29a strand target. The complement is then split into two shorter
4 sequences, 10 bases and 12 bases, respectively. The 10 base sequence is modified at the 5' end
5 using a thiol-(Hexaethylene glycol)₃ group and the 12 base sequence is modified at the 3' end
6 using a biotin moiety. The monothiolated DNA are then attached to the surface of a gold
7 nanoparticles, along with dye molecules (malachite green isothiocyanate, MGITC). The
8 nanoparticle conjugates are deposited onto the conjugate storage layer shown in **Figure 3**. The
9 biotin modified DNA is used to form a complex with streptavidin, which acts as an anchor
10 immobilizing the sequence on the nylon capture layer.
11
12

13 This is similar in design to our previous work with a solution-based sensing assay of fungal
14 infection specific DNA, whereby SERS signal enhancement is realized in the presence of a
15 complementary DNA target.³⁶ However, rather than tethering each probe to a set of gold
16 nanoparticles (AuNPs), only one probe is attached to the nanoparticle whilst the other is
17 anchored to a capture layer within the paper-based device (**Figure 3**). The assay has been
18 designed so that when the miR-29a is present, hybridization will occur in a two-step process: (i)
19 between the AuNP-DNA probe and miRNA strand and (ii) at the capture zone to tether the
20 nanoparticle in place causing a red spot to appear. Traditionally, this readout is interrogated using
21 RGB analysis, but deposition of the particles can often be heterogeneous and with limited
22 reproducibility.³⁷ In an attempt to overcome this issue, a portable Raman spectrometer was used
23 to measure the SERS response at the capture site. A Raman reporter, malachite green MGITC,
24 was attached to the AuNPs to provide a SERS signal that indicated the presence of miR-29a with
25 an expectation of a relationship between signal intensity and miRNA concentration.
26
27
28

29 To enable this multistep probe-target-probe hybridization sequence, we adapted a paper-
30 based microfluidic device that is capable of performing immunoassays by exchanging the type of
31 reagents stored within the device (e.g., use of DNA probes instead of antibodies).³⁸⁻⁴⁰ The three-
32 dimensional paper-based device consists of six layers of patterned paper or Nylon with each layer
33 serving a role in the detection of our desired analyte, miR-29a (**Figure 3A**). After an assay is
34 completed, peeling off the top three layers exposes the test zone on the readout layer. This
35 process reveals the nanoparticle tethering, permitting the captured gold complex to be
36 interrogated using RGB and SERS analysis.
37
38

39 Addition of the miR-29a sequence facilitates the retention of the RNA functionalized
40 nanoparticle at the readout site orientating in a 'tail-to-tail' configuration in relation to the
41 streptavidin anchor. It takes approximately 5 mins to run the sample through the device.
42 Optimization of running and suspension buffers was crucial in order to aid nanoparticle flow
43 through the device. The most crucial component was found to be the sucrose incorporated into
44 the suspension buffer. At concentrations below 10% w/v, functionalized nanoparticles would not
45 release from the conjugate storage layer after addition of a sample.
46

47 The functionalized AuNPs used in the assay had an optical density (O.D.) of 7. This
48 concentration of AuNPs was found to be optimal, allowing them to flow freely in the paper
49 devices while limiting non-specific adsorption. The concentration of miR-29a that was run
50 through the device is expressed in pg/ μ L (full calculation is shown in the SI). Six concentrations
51 ranging from 18 – 720 pg/ μ L plus a blank (miR-21 at 720 pg/ μ L) were used in the experiments.
52 Each concentration was interrogated in triplicate, and a spectrum was captured on each
53 deposition layer, providing a total of 24 spectra. Initial signal variation problems were
54 encountered by trying to manually ensure that the capture spot from each device was positioned
55
56
57
58
59
60

1
2
3 identically over the aperture. This variation was overcome by 3D printing a custom sample holder
4 optimized for sample distance (~28 mm covering the point and shoot adjustable tip) and capture
5 spot centering (facilitated by three support posts). Incidentally, the holder also restricts light
6 entering the aperture, which could otherwise provide background light interference to the SERS
7 spectrum (adaptor design is displayed in **Figure 2**).

8
9 There are 3 major vibrations arising from MGITC attached to the AuNPs surface, these are
10 positioned at 1174 cm⁻¹ (benzene in-plane vibration), 1364 cm⁻¹ (N-Ph ring stretch) and 1612 cm⁻¹
11 (N-Ph ring and C-C stretch). The peak at 1174 cm⁻¹ was used to calculate a concentration curve
12 (**Figure 4**, 18-360 pg/μL) because, apart from its high SERS signal, it is also a single band avoiding
13 the error concomitant with associated shoulders (for example, exhibited by the largest peak at
14 1364 cm⁻¹). The limit of detection (LoD) was estimated according to the following equation:
15
16

$$17 \text{LoD} = \text{LoB} + 1.645(\text{SD}_{\text{low concentration sample}})$$

18
19
20 Where the limit of the blank (LoB) is defined as:

$$21 \text{LoB} = \text{mean}_{\text{blank}} + 1.645(\text{SD}_{\text{blank}})$$

22
23
24
25 The LoD was estimated to be 47 pg/μL. When dry each device was scanned using a conventional
26 desktop scanner operating at 800 dpi. The scanned images were saved in TIFF format and
27 analyzed using Image J.⁴¹ The diameter of the readout site on the chips is 2.6 mm, but to generate
28 the RGB output using the RGB measure plugin (<https://imagej.nih.gov/ij/plugins/rgb-measure.html>), a circle of smaller diameter (approximately 2.2 mm) was used so as to avoid
29 interference from the printed yellow rings that were used to provide contrast. RGB values for
30 each of the concentrations (0 to 720 pg/μL) were extracted and normalized by subtracting their
31 values from 255. Plots showing the relationship between each of the channels (R, G and B)
32 normalized values with respect to miR-29a concentrations can be seen in **Figure 5**. The channels
33 all demonstrated a high goodness-of-fit implied by the linear regression models (R²) with the red
34 channel = 0.9523, green channel = 0.982 and blue channel = 0.9809. However, there is extensive
35 overlap in the standard deviations, especially at lower miRNA concentrations (highlighted in red
36 in **Figure 5**). The LoD for colorimetric analysis is estimated to be >200 pg/μL meaning that while
37 it provides effective qualitative discrimination of miR-29a concentration it cannot provide
38 reproducible semi-quantitative analysis to the same levels that SERS provides.
39

40
41
42
43
44 Detection of miRNA using DNA-AuNP probes has been demonstrated previously and have
45 been shown to achieve femtomolar LoDs.⁴² The application of SERS for the detection of miRNAs
46 has also been shown by multiple groups with LoDs ranging from 70.2 aM–1 pM.^{13, 43-47} While
47 these LoDs are excellent and demonstrate the future potential of noble metal nanoparticles and
48 SERS towards the detection of disease associated miRNAs, none of these methodologies are
49 amenable to POCT. The use of enzymes, circular amplification cycles, large instrumentation, and
50 solution-based analysis significantly complicates rapid detection of miRNA. The methods would
51 not adhere to the ASSURED guidelines and it would be challenging to adapt them for POCT.
52 However, the use of the handheld Raman instrument for the analysis of the paper-based devices
53 is consistent with interpretations for REASSURED criteria that consider handheld readers (e.g.,
54 cell phones, glucometers) for Real time connectivity as solutions to POCT in limited-resource
55
56
57
58
59
60

1
2
3 settings. Moreover, the use of Raman appears to forgo any substantial errors associated with
4 heterogeneous deposition on the capture layer. It is believed that the integrated orbital raster
5 scan (ORS) mode is helpful in maintaining integrity over a large area by using a tightly focused
6 beam with a patterned laser excitation. Relative standard deviations associated with each
7 concentration ranged from 3-12%, which is remarkable given the challenge for previously
8 obtaining reproducible behavior of SERS analysis and indicative of the future potential for
9 quantitative SERS measurements to be taken.
10

11
12 The work demonstrated here shows the huge potential for the combination of paper-
13 based devices with colorimetric analysis and portable Raman instrumentation for the validation
14 and semi-quantitative analysis of POCT. Implementation of future work associated with both
15 adapting the paper devices and carrying out SERS analysis is crucial to further improve the
16 sensitivity and specificity of the diagnostic method. It is also vital that multiplexed analysis of a
17 range of CVD associated circulating miRNA biomarkers can be detected to reinforce disease
18 diagnosis. SERS signals can also be improved to further enhance the sensitivity, which would
19 include exploring a range of nanoparticle sizes, morphologies and associated Raman reporters.
20
21

22
23 This work has been funded by the EPSRC Grant no. EP/L014165/1. This material is based upon
24 work supported by the National Science Foundation Graduate Research Fellowship Program
25 under Grant no. DGE-1325256 that was awarded to S.C.F. and was supported by a
26 generous gift from James Kanagy. Parts of Figures 1, 3 and 5 have been created with
27 Biorender.com.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 1. The schematic shows how the components comprising the split-probe hybridization assay are designed. A 22 base DNA strand complementary to the miR-29a sequence is first developed, then divide the split into two portions consisting of 10 and 12 bases. The 10 base sequences is modified at the 5' end using a thiol attached to 3 hexaethylene glycol groups (HEG). The functionalized oligos are then attached to the surface of the gold nanoparticles using a pH-modified methodology (procedure details are given in the experimental section of the manuscript) followed by the surface attachment of malachite green isothiocyanate Raman reporter. After attachment of the DNA and reporter the functionalized gold nanoparticles are deposited onto the conjugate storage layer of the device. For the capture portion of the assay a streptavidin-bound DNA complex is formed. To do this the 12 base sequences is functionalized with biotin at the 3' end. Streptavidin is then deposited on the capture layer and incubated with the biotin-modified DNA to form an immobilized complex. Unbound biotin-DNA is then removed through successive washes with 0.3 M PBS pH 7.4.



30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. (A) shows the design and dimensions of the Raman aperture adaptor used for the analysis of the capture layer contained within the 3-D paper device. The adaptor was appropriately scaled to ensure that readouts were made at the optimal distance and center of the spot (B) Images display how the adaptor fits over the point and shoot lens and how the capture layer is mounted to enable SERS analysis.




Figure 3. Illustration of the dual detection method for miR-29a in a 3D paper-based microfluidic device (A) Exploded schematic of the 3D paper device configuration. The dotted lines represent the sample pathway before the sample mixes with the AuNP conjugate (blue), after the sample rehydrates and mixes with the AuNP conjugate to form the partial immunocomplex (red) and as excess reagents and sample wick away from the capture zone (pink). (B) Representative images of sample readout using both colorimetric and SER methods for samples containing miR-29a (+ve) and samples without miR-29a (-ve).




Figure 4. Graphical representation of the SERS performance of miRNA assay in 3D paper-based microfluidic device using different concentrations of miR-29a (18-360 pg/μL). A. shows SERS spectra representative of the 18 pg/μL (blue) and 360 pg/μL (red) concentrations, highlighted are three signature MGITC peaks. The intensity of the tentatively assigned benzene in-plane vibration observed at 1174 cm⁻¹ was used to produce the SERS concentration curve seen in B. Each data point represents the average of 3 replicates and their associated errors. The trendline is fit to the data via a 2nd order polynomial. The limit of detection for miR-29a is estimated to be 47 pg/μL. An image representing each concentration of miR-29a analyzed is inset in the concentration curve.




Figure 5. The protocol for RGB analysis is shown in A. After completion of the tests the paper-based devices were scanned using a flatbed scanner set at a resolution of 800 dpi. The exported 8-bit images were then uploaded into ImageJ. A circle of 2.2 mm diameter was used to define an area on all the test readouts and RGB analysis was carried out using the RGB measure script. Graphical representation of the colorimetric analysis of the 3D paper-based microfluidic devices. Each of the channels R, G and B are represented in that order from left to right (A-C). Each plot shows the relationship between normalized channel intensity and miR-29a concentration (18-360 pg/ μ L). Average values and standard deviations were generated from 3 replicates. Linear regression gave R^2 values of 0.9523 (red channel), 0.982 (green channel) and 0.9809 (blue channel). Red markers at lower miR-29a concentrations are used to highlight significant overlaps in the standard deviations.

References

1. Cardiovascular Disease (CVDs), (accessed 13th July, 2019).
2. M. Tovar Pérez and M. R. Rodríguez Mondéjar, *Radiologia*, 2017, **59**, 446-459.
3. L. Capotosto, F. Massoni, S. De Sio, S. Ricci and A. Vitarelli, *BioMed Research International*, 2018, **2018**, 15.
4. E. A. Ashley, V. Raxwal and V. Froelicher, *Progress in Cardiovascular Diseases*, 2001, **44**, 55-67.
5. G. Graham, *Curr Cardiol Rev*, 2015, **11**, 238-245.
6. A. M. Caliendo, D. N. Gilbert, C. C. Ginocchio, K. E. Hanson, L. May, T. C. Quinn, F. C. Tenover, D. Alland, A. J. Blaschke, R. A. Bonomo, K. C. Carroll, M. J. Ferraro, L. R. Hirschhorn, W. P. Joseph, T. Karchmer, A. T. MacIntyre, L. B. Reller, A. F. Jackson and Idsa, *Clin Infect Dis*, 2013, **57**, S139-S170.
7. H.-J. Yu, S. Lim, M.-J. Kwon, H.-Y. Woo and H. Park, *Evaluation of Cobas b 101 HbA1c Analyzer Performance for Point-of-Care Testing*, 2017.
8. C. L. Martin, *The Clinical biochemist. Reviews*, 2010, **31**, 81-84.
9. I. Toskin, R. W. Peeling, D. Mabey, K. Holmes, R. Ballard, J. Kiarie and I. Askew, *Sexually Transmitted Infections*, 2017, **93**, S1.
10. K. J. Land, D. I. Boeras, X. S. Chen, A. R. Ramsay and R. W. Peeling, *Nat Microbiol*, 2019, **4**, 46-54.
11. A. K. Yetisen, M. S. Akram and C. R. Lowe, *Lab Chip*, 2013, **13**, 2210-2251.
12. J. Hu, X. Y. Cui, Y. Gong, X. Y. Xu, B. Gao, T. Wen, T. J. Lu and F. Xu, *Biotechnol. Adv.*, 2016, **34**, 305-320.
13. S. Ahmed, M. P. N. Bui and A. Abbas, *Biosens Bioelectron*, 2016, **77**, 249-263.
14. M. Sher, R. Zhuang, U. Demirci and W. Asghar, *Expert Rev Mol Diagn*, 2017, **17**, 351-366.
15. X. Fu, Z. Cheng, J. Yu, P. Choo, L. Chen and J. Choo, *Biosens Bioelectron*, 2016, **78**, 530-537.
16. M. Jauset-Rubio, M. Svobodova, T. Mairal, C. McNeil, N. Keegan, A. Saeed, M. N. Abbas, M. S. El-Shahawi, A. S. Bashammakh, A. O. Alyoubi and C. K. O'Sullivan, *Sci Rep-Uk*, 2016, **6**.
17. S. Takalkar, K. Baryeh and G. D. Liu, *Biosens Bioelectron*, 2017, **98**, 147-154.
18. P. F. Mens, A. van Amerongen, P. Sawa, P. A. Kager and H. D. F. H. Schallig, *Diagn Microb Infect Dis*, 2008, **61**, 421-427.
19. S. Choi, J. Hwang, S. Lee, D. W. Lim, H. Joo and J. Choo, *Sensor Actuat B-Chem*, 2017, **240**, 358-364.
20. J. S. Oh, G. W. Ha, Y. S. Cho, M. J. Mm, D. J. An, K. K. Hwang, Y. K. Lim, B. K. Park, B. K. Kang and D. S. Song, *Clinical and Vaccine Immunology*, 2006, **13**, 520-524.
21. H. Xu, X. Mao, Q. X. Zeng, S. F. Wang, A. N. Kawde and G. D. Liu, *Anal Chem*, 2009, **81**, 669-675.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
22. W. M. Leung, C. P. Chan, M. F. Leung, R. Renneberg, K. Lehmann, I. Renneberg, M. Lehmann, A. Hempel and J. F. C. Glatz, *Anal Lett*, 2005, **38**, 423-439.
23. J. S. Ahn, S. Choi, S. H. Jang, H. J. Chang, J. H. Kim, K. B. Nahm, S. W. Oh and E. Y. Choi, *Clin Chim Acta*, 2003, **332**, 51-59.
24. J. Boeddinghaus, R. Twerenbold, T. Nestelberger, P. Badertscher, K. Wildi, C. Puelacher, J. du Fay de Lavallaz, E. Keser, M. Rubini Giménez, D. Wussler, N. Kozhuharov, K. Rentsch, Ò. Miró, F. J. Martin-Sanchez, B. Morawiec, S. Stefanelli, N. Geigy, D. I. Keller, T. Reichlin and C. Mueller, *Clinical Chemistry*, 2018, **64**, 1347.
25. P. M. Ridker, *Clinical Chemistry*, 2009, **55**, 209.
26. R. Dhingra and R. S. Vasan, *Trends Cardiovasc Med*, 2017, **27**, 123-133.
27. M. K. Jensen, M. L. Bertoia, L. E. Cahill, I. Agarwal, E. B. Rimm and K. J. Mukamal, *Nature Reviews Endocrinology*, 2014, **10**, 659.
28. Y. Yang, E. Noviana, M. P. Nguyen, B. J. Geiss, D. S. Dandy and C. S. Henry, *Anal Chem*, 2017, **89**, 71-91.
29. S. C. Fernandes, J. A. Walz, D. J. Wilson, J. C. Brooks and C. R. Mace, *Anal Chem*, 2017, **89**, 5654-5664.
30. E. B. Strong, S. A. Schultz, A. W. Martinez and N. W. Martinez, *Sci Rep-Uk*, 2019, **9**, 7.
31. G. Xu, D. Nolder, J. Reboud, M. C. Oguike, D. A. van Schalkwyk, C. J. Sutherland and J. M. Cooper, *Angewandte Chemie International Edition*, 2016, **55**, 15250-15253.
32. M. Sher, R. Zhuang, U. Demirci and W. Asghar, *Expert Rev Mol Diagn*, 2017, **17**, 351-366.
33. R. Roncarati, C. Viviani Anselmi, M. A. Losi, L. Papa, E. Cavarretta, P. Da Costa Martins, C. Contaldi, G. Sacconi Jotti, A. Franzone, L. Galastri, M. V. G. Latronico, M. Imbriaco, G. Esposito, L. De Windt, S. Betocchi and G. Condorelli, *Journal of the American College of Cardiology*, 2014, **63**, 920-927.
34. P. K. Jain, K. S. Lee, I. H. El-Sayed and M. A. El-Sayed, *J Phys Chem B*, 2006, **110**, 7238-7248.
35. P. H. C. Eilers and H. F. M. Boelens, *Leide University Medical Centre Report*, 2005, 1-5.
36. S. Mabbott, D. Thompson, N. Sirimuthu, G. McNay, K. Faulds and D. Graham, *Faraday Discuss*, 2016, **187**, 461-472.
37. R. Derda, S. K. Tang, A. Laromaine, B. Mosadegh, E. Hong, M. Mwangi, A. Mammoto, D. E. Ingber and G. M. Whitesides, *Plos One*, 2011, **6**, e18940.
38. J. E. Schonhorn, S. C. Fernandes, A. Rajaratnam, R. N. Deraney, J. P. Rolland and C. R. Mace, *Lab Chip*, 2014, **14**, 4653-4658.
39. S. C. Fernandes, G. S. Logounov, J. B. Munro and C. R. Mace, *Anal Methods-Uk*, 2016, **8**, 5204-5211.
40. R. N. Deraney, C. R. Mace, J. P. Rolland and J. E. Schonhorn, *Anal Chem*, 2016, **88**, 6161-6165.
41. C. T. Rueden, J. Schindelin, M. C. Hiner, B. E. DeZonia, A. E. Walter, E. T. Arena and K. W. Eliceiri, *BMC Bioinformatics*, 2017, **18**, 529.
42. F. Degliangeli, P. Kshirsagar, V. Brunetti, P. P. Pompa and R. Fiammengo, *J Am Chem Soc*, 2014, **136**, 2264-2267.
43. L. P. Ye, J. Hu, L. Liang and C. Y. Zhang, *Chem Commun*, 2014, **50**, 11883-11886.
44. H. Zhang, Y. Yi, C. H. Zhou, G. Q. Ying, X. D. Zhou, C. P. Fu, Y. F. Zhu and Y. Q. Shen, *Rsc Adv*, 2017, **7**, 52782-52793.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
45. J. Su, D. F. Wang, L. Norbel, J. L. Shen, Z. H. Zhao, Y. Z. Dou, T. H. Peng, J. Y. Shi, S. Mathur, C. H. Fan and S. P. Song, *Anal Chem*, 2017, **89**, 2531-2538.
46. H. Zhang, Y. Liu, J. Gao and J. H. Zhen, *Chem Commun*, 2015, **51**, 16836-16839.
47. Y. He, X. Yang, R. Yuan and Y. Q. Chai, *Anal Chem*, 2017, **89**, 2866-2872.